Polypeptide vaccine for treating diseases caused by highly pathogenic avian influenza viruses H5N1

An avian influenza virus, H5N1 technology, applied in the field of biomedicine, can solve the problem of reducing the replication efficiency of mice, and achieve the effects of facilitating automated mass production, convenient transportation and storage, and obvious effects

Inactive Publication Date: 2011-06-08
CHONGQING UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Watanabe et al. found that after cutting off 11 amino acids at the hydroxyl end of H5N1 virus M2, the virus had similar growth ability compared with the wild type, but the replication efficiency in mice was greatly reduced

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Polypeptide vaccine for treating diseases caused by highly pathogenic avian influenza viruses H5N1
  • Polypeptide vaccine for treating diseases caused by highly pathogenic avian influenza viruses H5N1
  • Polypeptide vaccine for treating diseases caused by highly pathogenic avian influenza viruses H5N1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1: its amino acid sequence can be:

[0022]

[0023] The polypeptide can stimulate HLA-A*0201 positive human peripheral blood mononuclear cells in vitro, increase the number of these peripheral blood mononuclear cells transformed into cytotoxic T lymphocytes (CTL for short) by 60%, and activate CTL to dissolve For cells with the N1 gene of the highly pathogenic avian influenza virus H5N1, the lysis rate is 83.10%.

Embodiment 2

[0024] Embodiment 2: its amino acid sequence can also be:

[0025]

[0026] The polypeptide can stimulate peripheral blood mononuclear cells of HLA-A*0201 positive human body in vitro, increase the number of these peripheral blood mononuclear cells transformed into cytotoxic T lymphocytes (CTL for short) by 50%, and activate CTL to dissolve For cells with the N1 gene of the highly pathogenic avian influenza virus H5N1, the lysis rate is 79.0%.

Embodiment 3

[0027] Embodiment 3: its amino acid sequence can also be:

[0028]

[0029] The polypeptide can stimulate HLA-A*0201 positive human peripheral blood mononuclear cells in vitro, increase the number of these peripheral blood mononuclear cells transformed into cytotoxic T lymphocytes (CTL for short) by 55%, and activate CTL to dissolve For cells with the N1 gene of the highly pathogenic avian influenza virus H5N1, the lysis rate is 68.0%.

[0030] The amino acid sequence method described above is an existing mature technology, which is made according to the following method:

[0031] Adopt the standard Fmoc scheme, initially select 0.0125mmol, PSC resin (produced by ABI company, batch number A5F013), respectively according to the sequence characteristics described in claim 1, 2, 3 or 4, make the peptide chain extend from the C terminal to the N terminal one by one , the consumption of each amino acid raw material (produced by American ABI Company) is 0.1 mmol. Various amino ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a polypeptide vaccine for treating diseases caused by highly pathogenic avian influenza viruses H5N1 and relates to the field of biomedicine, in particular to a polypeptide vaccine for treating diseases caused by the highly pathogenic avian influenza viruses H5N1. The polypeptide vaccine is characterized in that the amino acid sequence of the polypeptide vaccine is amino-QIGNISWV-carboxyl; and the polypeptide vaccine forms a special connecting mode by utilizing the characteristics that the lysine has two amino groups and a carboxyl group and using the lysine as a joint. The polypeptide vaccine has the advantages of convenience for transportation and storage and automatic batch production and the capacity of activating specific cytotoxic T lymphocyte (CTL), wherein the specific CTL has the capacities of killing and dissolving target cells with the highly pathogenic avian influenza virus H5N1 protein, and the polypeptide vaccine has obvious effect and no toxic and side effects.

Description

(1) Technical field [0001] The invention relates to the field of biomedicine, in particular to a polypeptide vaccine for diseases caused by highly pathogenic avian influenza virus. (two), background technology [0002] Avian influenza (Avian influenza) is abbreviated as bird flu, which is a widespread infectious disease in poultry caused by type A influenza virus (AIV). According to incomplete statistics, the global bird flu epidemic has spread to 47 countries and regions, and there have been more than 195 cases of human bird flu, of which at least 110 people died, with a mortality rate as high as 56.4%. The avian flu that occurred in Hong Kong in 1997 caused human morbidity and death, which aroused great attention from all over the world. AIV can be divided into 16 H subtypes (H1-H16) and 10 N subtypes (N1-N10) according to the differences in the antigenicity of hemagglutinin (HA) and neuraminidase (NA). [Alexander DJ. A review of avian influenza in different bird species...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/145A61K38/08A61K38/10A61K38/16C07K7/06C07K7/08C07K14/00A61P31/16
Inventor 吕凤林田菲菲杨力
Owner CHONGQING UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap